valproic acid has been researched along with Adenocarcinoma, Follicular in 4 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid does not increase radioiodine uptake and does not have anticancer activity in patients with advanced, radioiodine-negative thyroid cancer of follicular cell origin." | 2.84 | A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. ( Kebebew, E; Merkel, R; Neychev, V; Nilubol, N; Patel, D; Reynolds, JC; Sadowski, SM; Yang, L, 2017) |
| "Valproic acid (VA) is an anticonvulsant that inhibits histone deacetylase activity at nontoxic concentrations." | 1.33 | Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. ( Chung, WY; Clark, OH; Duh, QY; Kebebew, E; Shen, WT; Wong, MG; Wong, TS, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nilubol, N | 1 |
| Merkel, R | 1 |
| Yang, L | 1 |
| Patel, D | 1 |
| Reynolds, JC | 1 |
| Sadowski, SM | 1 |
| Neychev, V | 1 |
| Kebebew, E | 3 |
| Xiao, X | 1 |
| Ning, L | 1 |
| Chen, H | 1 |
| Mitmaker, EJ | 1 |
| Griff, NJ | 1 |
| Grogan, RH | 1 |
| Sarkar, R | 1 |
| Duh, QY | 2 |
| Clark, OH | 2 |
| Shen, WT | 2 |
| Wong, TS | 1 |
| Chung, WY | 1 |
| Wong, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin[NCT01182285] | Phase 2 | 13 participants (Actual) | Interventional | 2010-09-24 | Completed | ||
| PLA General Hospital[NCT05920512] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01182285)
Timeframe: Date treatment consent signed to date off study, approximately 41 months and 11 days
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants | 8 |
Best overall response was assessed by radioiodine uptake. Complete response (CR) is increased Rai (radioiodine) uptake on post- valproic acid therapy at week 10, AND a decrease in Tg (thyroglobulin ) level to less than 2 ng/ml (or a decrease in Tg-Ab (thyroglobulin antibodies) level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. (NCT01182285)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Unknown | |
| B2 - Phase 2 Schedule 2 (No Increased Radiiodine Uptake) | 0 | 0 | 1 | 6 | 1 |
NIS (Na/I-symporter) Expression is assessed by quantitative reverse transcription (RT) polymerase chain reaction (PCR) and immunohistochemistry (IHC). NIS mRNA expression was measured by quantitative RT PCR from biopsy samples. (NCT01182285)
Timeframe: Entry to study and after 10 weeks of treatment
| Intervention | percent expression (Median) | |
|---|---|---|
| Pre-treatment NIS expression (relative to GAPDH) | Post-treatment NIS expression (relative to GAPDH) | |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | 21 | 25 |
Complete response (CR) is increased Rai uptake on post- valproic acid therapy at week 10, AND a decrease in Tg level to less than 2 ng/ml (or a decrease in Tg-Ab level to less than 2.0 IU/ml) at 10 weeks AND disappearance of all lesions at 16 weeks. Partial response (PR) is increased Rai uptake on post-valproic scan at week 10, OR a decreased Tg level (or a decrease in Tg Ab (Tg antibody) level by more than 20%) at 10 weeks AND 30% decrease in target lesion at 16 weeks. Stable disease (SD) is no change in RAI uptake AND Tg levels (or TG-Ab level) AND no significant change of lesions at 16 weeks. Progressive disease (PD) is tumor mass increases OR Tg levels (or Tg-Ab levels) increases over 10 weeks OR at least 20% increase in target lesion at 16 weeks. (NCT01182285)
Timeframe: Entry to study and after 10 weeks of treatment for Phase 1, and 10 weeks of treatment to 16 weeks of treatment for phase 2.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg start - >900 ng/ml | Tg start - 707 ng/ml | Tg start - 661 ng/ml | Tg start - 362 ng/ml | Tg start - 289 ng/ml | Tg start - 183 ng/ml | Tg start - 154 ng/ml | Tg start - 101 ng/ml | Tg start - 99 ng/ml | Tg start - 15.7 ng/ml | antiTg start - 142 IU/ml | antiTg start - 220 IU/ml | antiTg start - <20 IU/ml | Tg end - >900 ng/ml | Tg end - 749 ng/ml | Tg end - 702 ng/ml | Tg end - 630 ng/ml | Tg end - 480 ng/ml | Tg end - 362 ng/ml | Tg end - 204 ng/ml | Tg end - 184 ng/ml | Tg end - 183 ng/ml | Tg end - 128 ng/ml | Tg end - 61 ng/ml | Tg end - 10.8 ng/ml | Tg end - none | antiTg end - 338 IU/ml | anti Tg end - 220 IU/ml | antiTg end - 83 IU/ml | antiTg end - 80 IU/ml | anti Tg end - <20 IU/ml | antiTg end - none | RAI uptake pre-treatment - none | RAI uptake post treatment - none | |
| A - Phase 1 Radioiodine Resistant Thyroid Cancer | 6 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 5 | 1 | 13 | 10 |
| B2 - Phase 2 Schedule 2 (No Increased Radioiodine Uptake) | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
1 trial available for valproic acid and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Female; Histone Deacetylase Inhibitors; Humans; | 2017 |
3 other studies available for valproic acid and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Topics: Adenocarcinoma, Follicular; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Proliferation; | 2009 |
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Antimetabolites, Antineoplastic; Azacitidine; | 2011 |
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Apoptosis; Apoptosis Regulatory Proteins; Cel | 2005 |